SGB Raises Capital to Accelerate Cannabis Science and Technology

In April 2021, Supergalactic Brands closed a capital raise focused specifically on one thing: cannabis science and technology. Not brand marketing. Not retail expansion. Science — the foundational layer that everything else in the portfolio would eventually be built on.

The raise came at a pivotal moment. The cannabis edibles market was producing inconsistent products with inconsistent experiences. The beverage market was nascent. The extraction market was mature but fragmented. SGB's thesis was that the operator who controlled the underlying science would control the category outcomes — and that thesis required capital to prove.

What the Capital Was For

The 2021 raise funded three parallel investments: the incubation of Teeny Tiny Science and Dr. Noel Palmer's nano-emulsification platform; the strategic investment in QCi Labs and the Super Lab build; and the investment in KelSie Biotech's sublingual microdosing technology that would eventually become the foundation for SUM Microdose.

Three bets. All science. All infrastructure. None of them consumer-facing in 2021 — all of them powering consumer products by 2023.

We weren't raising money to launch a product. We were raising money to build the platform that would make every product we launched defensible.

The Return on the Investment

The 2021 capital raise funded a science platform that now powers eight brands, 17 SKUs, and 500+ retail locations. The PR%F Best of Show. The Grand Champion titles. The 5,000% revenue growth in Colorado. None of that happens without the infrastructure decisions made in 2021.

Supergalactic Brands · Capital raise 2021 · Cannabis science and technology